PMID- 28212363
OWN - NLM
STAT- MEDLINE
DCOM- 20170228
LR  - 20220317
IS  - 1543-0790 (Print)
IS  - 1543-0790 (Linking)
VI  - 14
IP  - 12
DP  - 2016 Dec
TI  - VEGF inhibitors in renal cell carcinoma.
PG  - 1016-1028
AB  - The arrival of targeted therapies-vascular endothelial growth factor (VEGF) 
      pathway inhibitors and mammalian target of rapamycin (mTOR) inhibitors-and 
      programmed death 1 (PD-1) inhibitors has transformed the management of renal cell 
      carcinoma (RCC). Once considered fatal, with a median survival of approximately 1 
      year, these agents have nearly tripled overall survival and have raised hopes of 
      a possible cure for advanced RCC. This review begins with a brief discussion of 
      the seminal von Hippel-Lindau/hypoxia-inducible factor axis in RCC. It then 
      discusses the pivotal trials that have investigated VEGF inhibitors in metastatic 
      RCC, as well as in adjuvant and neoadjuvant settings. Finally, it addresses some 
      practical considerations and future directions in the use of VEGF inhibitors in 
      RCC.
FAU - Vachhani, Pankit
AU  - Vachhani P
AD  - Roswell Park Cancer Institute, Buffalo, New York.
FAU - George, Saby
AU  - George S
AD  - Roswell Park Cancer Institute, Buffalo, New York.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Clin Adv Hematol Oncol
JT  - Clinical advances in hematology & oncology : H&O
JID - 101167661
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (VEGFA protein, human)
RN  - 0 (Vascular Endothelial Growth Factor A)
SB  - IM
MH  - Angiogenesis Inhibitors/*therapeutic use
MH  - Carcinoma, Renal Cell/*drug therapy
MH  - Humans
MH  - Kidney Neoplasms/*drug therapy
MH  - Vascular Endothelial Growth Factor A/*antagonists & inhibitors
EDAT- 2017/02/18 06:00
MHDA- 2017/03/01 06:00
CRDT- 2017/02/18 06:00
PHST- 2017/02/18 06:00 [entrez]
PHST- 2017/02/18 06:00 [pubmed]
PHST- 2017/03/01 06:00 [medline]
PST - ppublish
SO  - Clin Adv Hematol Oncol. 2016 Dec;14(12):1016-1028.